
OssDsign Q3 - Catalyst positively surprises, but still a difficult climate

Redeye is encouraged by the strong sales development, boosted by Catalyst contributing to c60% of US sales. While its spine product certainly positively surprised us, we emphasise a continuously challenging climate for elective surgeries and restricted hospital access, likely to depress sales in the medium term. We adjust our fair value range downwards following the report.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.

Attachments

[OssDsign Q3 - Catalyst positively surprises, but still a difficult climate](#)